Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001004540 | SCV001163608 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV001004540 | SCV001580907 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2020-06-27 | criteria provided, single submitter | clinical testing | This variant has been observed in individual(s) with classical galactosemia (PMID: 21150919). ClinVar contains an entry for this variant (Variation ID: 813466). This sequence change affects a donor splice site in intron 2 of the GALT gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is present in population databases (rs768154316, ExAC 0.01%). Experimental studies have shown that this variant disrupts mRNA splicing (PMID: 21150919). Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GALT are known to be pathogenic (PMID: 22944367). For these reasons, this variant has been classified as Pathogenic. |
Mayo Clinic Laboratories, |
RCV004792610 | SCV005413869 | pathogenic | not provided | 2024-01-30 | criteria provided, single submitter | clinical testing | PP4, PM2, PM3, PVS1 |
Natera, |
RCV001836062 | SCV002085187 | pathogenic | Galactosemia | 2020-01-19 | no assertion criteria provided | clinical testing |